Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322003 · ClinicalTrials.gov registry record · Phase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
A Phase 3 study of Amyotrophic Lateral Sclerosis, sponsored by Prilenia.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 3
- Study locations
NCT07322003 is a Phase 3 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Prilenia. The registered enrollment target is 500 participants, below the 893-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (44% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07322003, a Phase 3 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Prilenia.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pridopidine
Study Locations (3)
Massachusetts
- Sean M. Healey & AMG Center for ALS - Boston
Nebraska
- Somnos Clinical Research - Lincoln
Texas
- Texas Neurology - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07322003
The ClinicalTrials.gov registry entry for NCT07322003 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 893-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (44% lower). The listed sponsor is Prilenia, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07322003 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT07322003 about?
NCT07322003 is a clinical study titled "Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS". The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare...
What is the current status of trial NCT07322003?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2026-02-01. Estimated completion is 2029-03.
What conditions does trial NCT07322003 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT07322003?
The interventions under investigation include: Placebo (DRUG), Pridopidine (DRUG).
Who is sponsoring clinical trial NCT07322003?
This trial is sponsored by Prilenia, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07322003 being conducted?
This trial has 3 study locations across Massachusetts, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
RECRUITING · Phase 3
-
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
COMPLETED · Phase 3
-
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 3
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.